Protective effect of tetanus antibodies Hasan Tahsin Gozdas MD, Oguz Karabay MD PII: DOI: Reference:
S0735-6757(14)00328-3 doi: 10.1016/j.ajem.2014.05.009 YAJEM 54292
To appear in:
American Journal of Emergency Medicine
Received date: Revised date: Accepted date:
11 April 2014 12 April 2014 13 May 2014
Please cite this article as: Gozdas Hasan Tahsin, Karabay Oguz, Protective effect of tetanus antibodies, American Journal of Emergency Medicine (2014), doi: 10.1016/j.ajem.2014.05.009
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
ACCEPTED MANUSCRIPT Manuscript name: Protective effect of tetanus antibodies Manuscript type: Letter to the Editor
RI PT
Author names: Hasan Tahsin Gozdas MD; Oguz Karabay MD, Professor.
Department of Infectious Diseases and Clinical Microbiology, Sakarya University Faculty of
SC
Medicine, Sakarya, Turkey
NU
Corresponding author: Dr. Hasan Tahsin Gozdas
Medicine, Sakarya, Turkey
MA
Department of Infectious Diseases and Clinical Microbiology, Sakarya University Faculty of
PT ED
Tel: +902642552110 , Fax: +902642552102 e-mail: [email protected]
CE
Source of support: Nil
AC
Conflict of interest: None declared.
Dear Editor, We read recently published case report in your journal by Vollman et al. [1] with great interest. The authors described an interesting case that developed mild tetanus infection despite protective antibody level. The last booster vaccination is stated to have been administered 13 years prior to presentation. The high tetanus antibody level , measured after 10 days of exposure when the clinical symptoms appeared , however, may not be proetctive. This tetanus antibody level might be related to the recent natural infection [2]. To our
ACCEPTED MANUSCRIPT knowledge, antibodies could not prevent the occurrence of clinical disease, rather, they would provide that the disease course would be mild. If the tetanus antibody level could have
RI PT
been studied soon after exposure, this would reflect baseline protective level and would have substantiated the authors’ conclusion. References:
SC
1. Vollman KE, Acquisto NM, Bodkin RP. A case of tetanus infection in an adult with a
NU
protective tetanus antibody level. Am J Emerg Med. 2014; 32 (4): 392.e3-4. 2. Crone NE, Reder AT. Severe tetanus in immunized patients with high anti-tetanus titers.
AC
CE
PT ED
MA
Neurology. 1992; 42 (4): 761-4.
S0735-6757(14)00328-3 doi: 10.1016/j.ajem.2014.05.009 YAJEM 54292
To appear in:
American Journal of Emergency Medicine
Received date: Revised date: Accepted date:
11 April 2014 12 April 2014 13 May 2014
Please cite this article as: Gozdas Hasan Tahsin, Karabay Oguz, Protective effect of tetanus antibodies, American Journal of Emergency Medicine (2014), doi: 10.1016/j.ajem.2014.05.009
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
ACCEPTED MANUSCRIPT Manuscript name: Protective effect of tetanus antibodies Manuscript type: Letter to the Editor
RI PT
Author names: Hasan Tahsin Gozdas MD; Oguz Karabay MD, Professor.
Department of Infectious Diseases and Clinical Microbiology, Sakarya University Faculty of
SC
Medicine, Sakarya, Turkey
NU
Corresponding author: Dr. Hasan Tahsin Gozdas
Medicine, Sakarya, Turkey
MA
Department of Infectious Diseases and Clinical Microbiology, Sakarya University Faculty of
PT ED
Tel: +902642552110 , Fax: +902642552102 e-mail: [email protected]
CE
Source of support: Nil
AC
Conflict of interest: None declared.
Dear Editor, We read recently published case report in your journal by Vollman et al. [1] with great interest. The authors described an interesting case that developed mild tetanus infection despite protective antibody level. The last booster vaccination is stated to have been administered 13 years prior to presentation. The high tetanus antibody level , measured after 10 days of exposure when the clinical symptoms appeared , however, may not be proetctive. This tetanus antibody level might be related to the recent natural infection [2]. To our
ACCEPTED MANUSCRIPT knowledge, antibodies could not prevent the occurrence of clinical disease, rather, they would provide that the disease course would be mild. If the tetanus antibody level could have
RI PT
been studied soon after exposure, this would reflect baseline protective level and would have substantiated the authors’ conclusion. References:
SC
1. Vollman KE, Acquisto NM, Bodkin RP. A case of tetanus infection in an adult with a
NU
protective tetanus antibody level. Am J Emerg Med. 2014; 32 (4): 392.e3-4. 2. Crone NE, Reder AT. Severe tetanus in immunized patients with high anti-tetanus titers.
AC
CE
PT ED
MA
Neurology. 1992; 42 (4): 761-4.
